CD47 and neoplasm: Studies have shown that the overall survival (OS) and progression-free survival (PFS) of DLBCL patients, especially those with the activated B-cell-like (ABC) subtype, are significantly reduced when both CD47 on tumor cells and SIRPα in stromal cells are upregulated or when only SIRPα expression is increased.